Robot-Assisted Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of Urinary Bladder: A Comparison Between Intracorporeal Versus Extracorporeal Orthotopic Ileal Neobladder.

Journal: Journal of endourology
Published Date:

Abstract

To compare surgical, oncologic, functional outcomes and complication rate between intracorporeal neobladder (ICNB) and extracorporeal neobladder (ECNB) orthotopic ileal neobladder of robot-assisted radical cystectomy (RARC) in patients with nonmetastatic bladder carcinoma (BC). From 2014 to 2019, we prospectively collected and retrospectively analyzed 101 patients with nonmetastatic BC treated with RARC and ortothopic neobladder. Chi-squared test estimated differences in proportions of functional and oncologic outcomes. Multivariable logistic regression models (MLRMs) focused on overall, early (<30 days from discharge), and late complication rate (>30 days from discharge) in ICNB ECNB. Of all patients, 57 (56.4%) ICNB and 44 (43.6%) ECNB patients were identified. At least one complication occurred in 75.4% 72.7% in ICNB ECNB, respectively ( = 0.9). In MLRMs, focusing on complication rate, there was no statistically significant difference between ICNB ECNB for overall ( = 0.8), early ( = 0.6), and late complications ( = 0.8). No statistically significant differences were recorded for tumor relapse rate, cancer-specific and other cause mortality. No positive surgical margins were recorded in both groups. Daytime and nighttime continence recovery were 89.4% 87.1% ( = 1.0) and 63.8% 51.6% ( = 1.0) for ICNB ECNB. Potency recovery was 59.1% 54.3% ( = 0.5) for ICNB ECNB. No statistically significant differences in complication rate (overall, early, or late) were identified, when ICNB and ECNB were compared. Similarly, no statistically significant difference was found in oncologic and functional outcomes.

Authors

  • Francesco Alessandro Mistretta
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Gennaro Musi
    Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Claudia Collà Ruvolo
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Andrea Conti
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Stefano Luzzago
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Michele Catellani
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Ettore Di Trapani
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Gabriele Cozzi
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Roberto Bianchi
    Department of Urology, European Institute of Oncology (IEO), Via Giuseppe Ripamonti, 435, 20141, Milan, Italy.
  • Matteo Ferro
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Antonio Cioffi
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Giovanni Cordima
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Antonio Brescia
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Fabrizio Verweij
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Danilo Bottero
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Deliu Victor Matei
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Vincenzo Mirone
    Department of Urology, Federico II University, Naples, Italy.
  • Ottavio De Cobelli
    Department of Urology, European Institute of Oncology (IEO), Via Giuseppe Ripamonti, 435, 20141, Milan, Italy.